- Home
- STR vs GRDN Comparison
STR vs GRDN Comparison
Compare STR & GRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STR
- GRDN
- Stock Information
- Founded
- STR 2016
- GRDN 2004
- Country
- STR United States
- GRDN United States
- Employees
- STR N/A
- GRDN N/A
- Industry
- STR Oil & Gas Production
- GRDN Retail-Drug Stores and Proprietary Stores
- Sector
- STR Energy
- GRDN Consumer Staples
- Exchange
- STR Nasdaq
- GRDN Nasdaq
- Market Cap
- STR 1.4B
- GRDN 1.6B
- IPO Year
- STR N/A
- GRDN 2024
- Fundamental
- Price
- STR $19.65
- GRDN $20.13
- Analyst Decision
- STR Buy
- GRDN Strong Buy
- Analyst Count
- STR 6
- GRDN 2
- Target Price
- STR $25.40
- GRDN $24.50
- AVG Volume (30 Days)
- STR 1.9M
- GRDN 416.9K
- Earning Date
- STR 08-06-2025
- GRDN 08-15-2025
- Dividend Yield
- STR 6.82%
- GRDN N/A
- EPS Growth
- STR N/A
- GRDN N/A
- EPS
- STR 0.52
- GRDN N/A
- Revenue
- STR $636,538,000.00
- GRDN $1,282,307,000.00
- Revenue This Year
- STR N/A
- GRDN $12.01
- Revenue Next Year
- STR N/A
- GRDN $2.33
- P/E Ratio
- STR $37.74
- GRDN N/A
- Revenue Growth
- STR 7.18
- GRDN 19.55
- 52 Week Low
- STR $14.58
- GRDN $14.16
- 52 Week High
- STR $25.64
- GRDN $26.91
- Technical
- Relative Strength Index (RSI)
- STR 57.00
- GRDN N/A
- Support Level
- STR $19.98
- GRDN N/A
- Resistance Level
- STR $20.78
- GRDN N/A
- Average True Range (ATR)
- STR 0.63
- GRDN 0.00
- MACD
- STR 0.03
- GRDN 0.00
- Stochastic Oscillator
- STR 68.44
- GRDN 0.00
About STR Sitio Royalties Corp.
Sitio Royalties Corp is a pure-play mineral and royalty company. The group focuses on investing in mineral and royalty interests in the Permian and other productive U.S. oil basins.
About GRDN Guardian Pharmacy Services Inc. Class A Common Stock
Guardian Pharmacy Services Inc is a differentiated pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of LTCFs adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. The company emphasizes high-touch, individualized clinical, drug dispensing, and administration capabilities that are tailored to serve the needs of residents in historically lower acuity LTCFs, such as ALFs and BHFs. The operating segment derives its revenues through sales of pharmaceutical and medical products, and all revenues are derived solely in the United States.